PBM & Pharmacy Benefit Management

A CFO who already speaks PBM.

Rebate economics, spread, administrative fees, and pass-through pricing are not something most finance leaders ramp into. They are the economics I work in. CFO advisory for pharmacy benefit managers, rebate aggregators, and the data and services businesses built around them.

$95M
Sale of Medicx Health to OptimizeRx (NASDAQ: OPRX), October 2023
$15–40M
Revenue scaled from a declining base through stabilization and growth
20%+
EBITDA margin, built from break-even post-stabilization
25+
Years in operating finance across healthcare, PBM, tech, and services
The Wedge

Why a generalist CFO struggles in PBM.

Pharmacy benefit management runs on economics that do not look like any other industry. Revenue is layered across administrative fees, rebate retention, spread, and increasingly pass-through arrangements where the margin moves to service and data. A finance leader who has not lived inside those mechanics spends the first two quarters learning the vocabulary instead of running the business.

That ramp is expensive. In a market where plan sponsors, consultants, and regulators are all pushing toward transparency, the CFO seat has to model the difference between a traditional spread book and a transparent pass-through book in real terms... what it does to gross margin, to cash timing on rebate receivables, and to the multiple a buyer will pay. That is not a textbook exercise. It is pattern recognition built from running the numbers.

Medicx Health is the exit credential... a healthcare data business scaled from a declining base to a $95M sale. The PBM fluency is separate and hands-on: pharmacy, rebate, and payor economics are the terrain I work in, not a vertical I am ramping into.

What the work covers

This is acting CFO and CFO advisory work, scoped to the situation rather than billed by the hour. The common threads in PBM and PBM-adjacent engagements:

  • Rebate and spread economics. Modeling retention, guarantees, and pass-through structures so leadership and the board see true margin, not gross billings.
  • Cash and working capital. Rebate receivables and pharmacy payables create timing gaps that can mask or distort real liquidity. Building the visibility to manage it.
  • Pricing and unit economics. Per-claim, per-member, and per-script economics that hold up when a sophisticated plan sponsor or consultant pressure-tests them.
  • KPI and reporting maturity. The operating metrics a PBM board actually needs, separated from the vanity numbers that hide risk.
  • Transaction readiness. Quality-of-earnings-grade EBITDA, contract durability, and customer concentration analysis before a buyer's diligence team finds the problems first.

Who this is for

The fit is founder-led or PE-backed companies, generally in the $5M to $100M revenue range, where finance has to lead rather than just report. That includes standalone PBMs, rebate aggregators, specialty and mail-order pharmacy businesses, and the technology and data companies that sell into them. Common trigger moments: a capital raise, a recapitalization, exit preparation, a turnaround under cash or margin pressure, or post-close value creation under new ownership.

If the business is below that range but the founder knows something in the financial picture is off, the right first step is usually a Pulse Check... a fixed-fee, 30-day diagnostic on cash, margin, and KPI maturity that produces a prioritized action memo. It is the lowest-risk way to get a senior read before committing to anything larger.

What this is not

This is not bookkeeping, controllership, or claims operations. It is the strategic finance seat... the person who sits between the CEO, the board, and a future buyer and makes sure the numbers tell a story that is both true and defensible.

Common Questions

Answers before the call.

The questions that come up first when a founder or sponsor is sizing up the fit.

What makes a PBM CFO different from a general healthcare CFO?+
PBM economics center on rebate retention, spread, administrative fees, and pass-through pricing. A general healthcare CFO often understands payor and provider economics but not the specific margin mechanics of a benefit manager. The difference shows up fastest in how true gross margin and rebate-receivable cash timing get modeled.
Do you work with rebate aggregators and pharmacy businesses, not just PBMs?+
Yes. The engagement scope covers standalone PBMs, rebate aggregators, specialty and mail-order pharmacy, and the technology and data companies that sell into the PBM market. The shared thread is complex, layered revenue economics.
What size company is the right fit?+
Generally $5M to $100M in revenue, founder-led or PE-backed. Below that range, a fixed-fee Pulse Check diagnostic is usually the better starting point than a full retainer.
How are PBM advisory engagements priced?+
Flat-fee and scoped, not hourly. Retainers run on a monthly cadence; project engagements carry defined deliverables and timelines. A 30-day Pulse Check diagnostic is available as a low-commitment on-ramp.
Can you help prepare a PBM business for sale?+
Yes. Transaction readiness is a core part of the work: quality-of-earnings-grade EBITDA, contract durability, customer concentration, and the financial narrative a buyer's diligence team will test. I led a healthcare data business through a $95M sale to a public acquirer.
Next Step

Talk through the PBM picture.

A 30-minute call is enough to tell whether the fit is real. No pitch deck, no obligation... just a direct read on where finance can take the business next.